NCT03172793View on ClinicalTrials.gov

Telavancin Pharmacokinetics in Cystic Fibrosis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 8, 2017

Primary Completion Date

April 17, 2019

Study Completion Date

April 17, 2019

Conditions
Cystic Fibrosis
Interventions
DRUG

Telavancin Injection

Receive 3 doses of telavancin as described in arm/groups, followed by collection of blood for pharmacokinetic analyses.

Trial Locations (5)

15232

University of Pittsburgh Medical Center Shadyside, Pittsburgh

19134

St. Christophers Hospital for Children, Philadelphia

46202

IU Health University Hospital, Indianapolis

Riley Hospital for Children, Indianapolis

06102

Hartford Hospital, Hartford

Sponsors
All Listed Sponsors
collaborator

Cumberland Pharmaceuticals, Inc.

UNKNOWN

lead

Joseph L. Kuti, PharmD

OTHER